KEYTRUDA POWDER (pembrolizumab)
MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Indication
PD-L1 positive esophageal carcinoma
PD-L1 positive esophageal carcinoma refers to epithelial malignancies of the esophagus—chiefly esophageal squamous cell carcinoma or adenocarcinoma—that demonstrate programmed death-ligand 1 (PD-L1) expression on tumor or infiltrating immune cells, typically quantified via immunohistochemistry using scores such as the Combined Positive Score (CPS) or Tumor Proportion Score (TPS). Read more about PD-L1 positive esophageal carcinoma
3 drugs 1 manufacturers
Drugs that treat it
Common PD-L1 positive esophageal carcinoma therapies.
KEYTRUDA (pembrolizumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
KEYTRUDA QLEX (pembrolizumab-berahyaluronidase alfa-pmph)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+33
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with PD-L1 positive esophageal carcinoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPD-L1 positive esophageal carcinoma refers to epithelial malignancies of the esophagus—chiefly esophageal squamous cell carcinoma or adenocarcinoma—that demonstrate programmed death-ligand 1 (PD-L1) expression on tumor or infiltrating immune cells, typically quantified via immunohistochemistry using scores such as the Combined Positive Score (CPS) or Tumor Proportion Score (TPS).
This biomarker-defined oncologic condition affects the digestive tract and is characterized by the upregulation of PD-L1, which engages PD-1 receptors on cytotoxic T lymphocytes to induce immune evasion and sustain malignant proliferation.
Often evaluated in locally advanced, unresectable, or metastatic disease stages, PD-L1 positivity serves as a critical predictive phenotype that identifies tumors with an immunosuppressive microenvironment likely to respond to immune checkpoint inhibitor therapies.
- arupconsult.com
PD-L1 positive esophageal carcinoma refers to epithelial malignancies of the esophagus—chiefly esophageal squamous cell carcinoma or adenocarcinoma—that demonstrate programmed death-ligand 1 (PD-L1) expression on tumor or infiltrating immune cells, typically quantified via immunohistochemistry using scores such as the Combined Positive Score (CPS) or Tumor Proportion Score (TPS)
- fda.gov
PD-L1 positive esophageal carcinoma refers to epithelial malignancies of the esophagus—chiefly esophageal squamous cell carcinoma or adenocarcinoma—that demonstrate programmed death-ligand 1 (PD-L1) expression on tumor or infiltrating immune cells, typically quantified via immunohistochemistry using scores such as the Combined Positive Score (CPS) or Tumor Proportion Score (TPS)
- nih.gov
PD-L1 positive esophageal carcinoma refers to epithelial malignancies of the esophagus—chiefly esophageal squamous cell carcinoma or adenocarcinoma—that demonstrate programmed death-ligand 1 (PD-L1) expression on tumor or infiltrating immune cells, typically quantified via immunohistochemistry using scores such as the Combined Positive Score (CPS) or Tumor Proportion Score (TPS) This biomarker-defined oncologic condition affects the digestive tract and is characterized by the upregulation of PD-...
- nih.gov
This biomarker-defined oncologic condition affects the digestive tract and is characterized by the upregulation of PD-L1, which engages PD-1 receptors on cytotoxic T lymphocytes to induce immune evasion and sustain malignant proliferation
- curetoday.com
Often evaluated in locally advanced, unresectable, or metastatic disease stages, PD-L1 positivity serves as a critical predictive phenotype that identifies tumors with an immunosuppressive microenvironment likely to respond to immune checkpoint inhibitor therapies
- cancernetwork.com
Often evaluated in locally advanced, unresectable, or metastatic disease stages, PD-L1 positivity serves as a critical predictive phenotype that identifies tumors with an immunosuppressive microenvironment likely to respond to immune checkpoint inhibitor therapies
Personalize your experience
Follow PD-L1 positive esophageal carcinoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.